Recent MIRA News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:15:12 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/19/2024 04:15:12 AM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 08/16/2024 08:05:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:06:29 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/12/2024 12:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:54:37 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/26/2024 08:55:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/26/2024 08:49:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:07:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:12:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:00:40 PM
- MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing • PR Newswire (US) • 06/24/2024 12:30:00 PM
- Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:00:06 PM
- Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance • PR Newswire (US) • 05/29/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:30:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:42:53 PM
- MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog • PR Newswire (US) • 05/21/2024 12:45:00 PM
- Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog • PR Newswire (US) • 05/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:31:03 PM
- Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission • PR Newswire (US) • 04/02/2024 12:00:00 PM
- MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor • PR Newswire (US) • 03/21/2024 03:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:45:16 PM
- MIRA Pharmaceuticals Provides Corporate Update • PR Newswire (US) • 02/05/2024 01:30:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM